[S02DA03, antipyrine, The metabolism of Thiothixene can be decreased when combined with Antipyrine.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Thiothixene.]
[J01EC01, sulfamethoxazole, The risk or severity of QTc prolongation can be increased when Sulfamethoxazole is combined with Thiothixene.]
[S01AB02, sulfisoxazole, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Sulfisoxazole.]
[N05AL01, sulpiride, Thiothixene may increase the antipsychotic activities of Sulpiride.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Thiothixene is combined with Sulthiame.]
[N06DA01, tacrine, The metabolism of Thiothixene can be decreased when combined with Tacrine.]
[L02BA01, tamoxifen, The risk or severity of QTc prolongation can be increased when Tamoxifen is combined with Thiothixene.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Thiothixene.]
[L01CB02, teniposide, Teniposide may increase the neurotoxic activities of Thiothixene.]
[R03CC03, terbutaline, The risk or severity of QTc prolongation can be increased when Terbutaline is combined with Thiothixene.]
[N07XX06, tetrabenazine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrabenazine.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tetracaine.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[N04BC07, apomorphine, The therapeutic efficacy of Apomorphine can be decreased when used in combination with Thiothixene.]
[L04AX02, thalidomide, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The metabolism of Thiothixene can be decreased when combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Thiothixene can be decreased when combined with Theophylline.]
[P02CA02, thiabendazole, The metabolism of Thiothixene can be decreased when combined with Thiabendazole.]
[L01XX41, eribulin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Eribulin.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Thiothixene.]
[N05CA19, thiopental, The risk or severity of adverse effects can be increased when Thiopental is combined with Thiothixene.]
[N05AB08, thioproperazine, The risk or severity of adverse effects can be increased when Thioproperazine is combined with Thiothixene.]
[N05AC02, thioridazine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Thioridazine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Thiothixene can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tilidine.]
[S01ED01, timolol, The metabolism of Timolol can be decreased when combined with Thiothixene.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tolperisone.]
[N02AX02, tramadol, The metabolism of Tramadol can be decreased when combined with Thiothixene.]
[N06AF04, tranylcypromine, The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Thiothixene.]
[N06AX05, trazodone, The risk or severity of QTc prolongation can be increased when Trazodone is combined with Thiothixene.]
[C03DB02, triamterene, The metabolism of Thiothixene can be decreased when combined with Triamterene.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Thiothixene.]
[A03AB12, mepenzolate, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[N05AB06, trifluoperazine, The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Thiothixene.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Trifluperidol.]
[N05AA05, triflupromazine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, The therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Thiothixene.]
[A03AA05, trimebutine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Alimemazine is combined with Thiothixene.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Thiothixene.]
[N06AA06, trimipramine, The risk or severity of adverse effects can be increased when Trimipramine is combined with Thiothixene.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Thiothixene.]
[A03BB01, butylscopolamine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Vilazodone is combined with Thiothixene.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Thiothixene.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Tubocurarine is combined with Thiothixene.]
[R03DX07, roflumilast, The metabolism of Roflumilast can be decreased when combined with Thiothixene.]
[L01EX04, vandetanib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Vandetanib.]
[L02BX03, abiraterone, The serum concentration of Thiothixene can be increased when it is combined with Abiraterone.]
[J05AG05, rilpivirine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Rilpivirine.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Ezogabine.]
[R03AC18, indacaterol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Indacaterol.]
[C08DA01, verapamil, The metabolism of Thiothixene can be decreased when combined with Verapamil.]
[N06AX09, viloxazine, The metabolism of Thiothixene can be decreased when combined with Viloxazine.]
[L01CA02, vincristine, Vincristine may increase the neurotoxic activities of Thiothixene.]
[B01AA03, warfarin, The metabolism of Thiothixene can be decreased when combined with Warfarin.]
[J01MB04, pipemidic acid, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Pipemidic acid.]
[N05AF05, zuclopenthixol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Levetiracetam is combined with Thiothixene.]
[L01EC01, vemurafenib, The serum concentration of Thiothixene can be increased when it is combined with Vemurafenib.]
[L01ED01, crizotinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Crizotinib.]
[M05BA06, ibandronic acid, The risk or severity of QTc prolongation can be increased when Ibandronate is combined with Thiothixene.]
[J01MA13, trovafloxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Trovafloxacin.]
[N05AE04, ziprasidone, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ziprasidone.]
[G04BD07, tolterodine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[L03AB11, peginterferon alfa-2a, The metabolism of Thiothixene can be decreased when combined with Peginterferon alfa-2a.]
[J02AC03, voriconazole, The risk or severity of QTc prolongation can be increased when Voriconazole is combined with Thiothixene.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Thiothixene is combined with Atracurium.]
[S01FA01, atropine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[L01EK01, axitinib, The metabolism of Axitinib can be decreased when combined with Thiothixene.]
[L04AX01, azathioprine, The metabolism of Thiothixene can be decreased when combined with Azathioprine.]
[M03BX01, baclofen, Baclofen may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Lorcaserin is combined with Thiothixene.]
[G04BD12, mirabegron, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Mirabegron.]
[L04AA31, teriflunomide, The serum concentration of Thiothixene can be decreased when it is combined with Teriflunomide.]
[N05CA04, barbital, The risk or severity of adverse effects can be increased when Barbital is combined with Thiothixene.]
[J05AE04, nelfinavir, The risk or severity of QTc prolongation can be increased when Nelfinavir is combined with Thiothixene.]
[L01AA09, bendamustine, The metabolism of Bendamustine can be decreased when combined with Thiothixene.]
[S01GA07, brimonidine, Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[N04BD02, rasagiline, The therapeutic efficacy of Rasagiline can be decreased when used in combination with Thiothixene.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Thiothixene is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Thiothixene.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Thiothixene.]
[R06AC06, thonzylamine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Thiothixene is combined with Diethyl ether.]
[H01CB05, pasireotide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Pasireotide.]
[J04AK05, bedaquiline, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Bedaquiline.]
[C04AX11, bencyclane, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Bencyclane.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Pomalidomide.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Benperidol.]
[J01MA15, gemifloxacin, The metabolism of Thiothixene can be decreased when combined with Gemifloxacin.]
[S01AE07, moxifloxacin, The metabolism of Thiothixene can be decreased when combined with Moxifloxacin.]
[A06AX06, tegaserod, The metabolism of Thiothixene can be decreased when combined with Tegaserod.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Benzocaine is combined with Thiothixene.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Thiothixene.]
[N04AC01, benztropine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Benzatropine.]
[L01EC02, dabrafenib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dabrafenib.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Benzyl alcohol.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Thiothixene is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Bepridil.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Vortioxetine is combined with Thiothixene.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Thiothixene can be decreased when combined with Simeprevir.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Vigabatrin is combined with Thiothixene.]
[A10BK01, dapagliflozin, The metabolism of Thiothixene can be decreased when combined with Dapagliflozin.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Thiothixene can be increased when combined with Apremilast.]
[S01ED02, betaxolol, The metabolism of Thiothixene can be decreased when combined with Betaxolol.]
[L04AC11, siltuximab, The metabolism of Thiothixene can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ceritinib.]
[A03BA03, hyoscyamine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The metabolism of Thiothixene can be decreased when combined with Acenocoumarol.]
[L01XH04, belinostat, The metabolism of Thiothixene can be increased when combined with Belinostat.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Alfaxalone.]
[R03AC19, olodaterol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Olodaterol.]
[D11AA01, glycopyrronium, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[N05CM19, suvorexant, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Eliglustat.]
[N05AA04, acepromazine, The risk or severity of adverse effects can be increased when Acepromazine is combined with Thiothixene.]
[N04AA02, biperiden, The therapeutic efficacy of Biperiden can be decreased when used in combination with Thiothixene.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Thiothixene.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Dicoumarol.]
[N06AX11, mirtazapine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Thiothixene can be increased when combined with Secukinumab.]
[L01EX08, lenvatinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Lenvatinib.]
[L01XH03, panobinostat, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Panobinostat.]
[N02BE01, acetaminophen, The metabolism of Thiothixene can be decreased when combined with Acetaminophen.]
[A03AA09, difemerine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tioclomarol.]
[C01EB17, ivabradine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ivabradine.]
[N05AX16, brexpiprazole, The risk or severity of adverse effects can be increased when Thiothixene is combined with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Thiothixene is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Cariprazine.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Thiothixene.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Acetophenazine is combined with Thiothixene.]
[L01EB04, osimertinib, The serum concentration of Thiothixene can be decreased when it is combined with Osimertinib.]
[G04CA01, alfuzosin, The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Thiothixene.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Aprobarbital is combined with Thiothixene.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Bromazepam is combined with Thiothixene.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be decreased when used in combination with Thiothixene.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Alverine is combined with Thiothixene.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiothixene.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Thiothixene is combined with Amineptine.]
[N05AX17, pimavanserin, Thiothixene may increase the neurotoxic activities of Pimavanserin.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Aniracetam.]
[A05AA04, obeticholic acid, The metabolism of Thiothixene can be decreased when combined with Obeticholic acid.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Thiothixene.]
[C07AA19, bupranolol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Bupranolol.]
[N07BC01, buprenorphine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[L02AE01, buserelin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Buserelin.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Thiothixene.]
[L01XX27, arsenic trioxide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Arsenic trioxide.]
[P01BE02, artemether, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Artemether.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Thiothixene.]
[J01MA09, sparfloxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Sparfloxacin.]
[R06AX09, azatadine, The risk or severity of QTc prolongation can be increased when Azatadine is combined with Thiothixene.]
[S01GX07, azelastine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Thiothixene can be increased when combined with Rucaparib.]
[S01AA26, azithromycin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Azithromycin.]
[L01EF02, ribociclib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ribociclib.]
[R03DA08, bamifylline, The metabolism of Bamifylline can be decreased when combined with Thiothixene.]
[N07XX16, deutetrabenazine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Deutetrabenazine.]
[N02BF02, pregabalin, The therapeutic efficacy of Thiothixene can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Beclamide.]
[N06BC01, caffeine, The metabolism of Thiothixene can be decreased when combined with Caffeine.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Thiothixene.]
[J01XX08, linezolid, The risk or severity of adverse effects can be increased when Linezolid is combined with Thiothixene.]
[L04AB02, infliximab, The metabolism of Thiothixene can be increased when combined with Infliximab.]
[N04BD03, safinamide, The therapeutic efficacy of Safinamide can be decreased when used in combination with Thiothixene.]
[J01MA23, delafloxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Delafloxacin.]
[L01XX59, enasidenib, The metabolism of Thiothixene can be decreased when combined with Enasidenib.]
[L01XH01, vorinostat, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Vorinostat.]
[A02BX12, bismuth subnitrate, Thiothixene may increase the neurotoxic activities of Bismuth subnitrate.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Thiothixene.]
[N04AA11, bornaprine, The therapeutic efficacy of Bornaprine can be decreased when used in combination with Thiothixene.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Brotizolam.]
[N04BX03, budipine, The therapeutic efficacy of Budipine can be decreased when used in combination with Thiothixene.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Butobarbital is combined with Thiothixene.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Thiothixene is combined with Butriptyline.]
[C01AA02, acetyldigoxins, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Acetyldigoxin.]
[N01BX04, capsaicin, The metabolism of Thiothixene can be increased when combined with Capsaicin.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Thiothixene is combined with Vinylbital.]
[R06AX18, acrivastine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Acrivastine.]
[V04CD06, macimorelin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Macimorelin.]
[N03AF01, carbamazepine, The metabolism of Thiothixene can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Thiothixene.]
[L03AB06, interferon alfa-n1, The metabolism of Thiothixene can be decreased when combined with Interferon alfa-n1.]
[C07AG02, carvedilol, The metabolism of Thiothixene can be decreased when combined with Carvedilol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Thiothixene.]
[L01EC03, encorafenib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Encorafenib.]
[L01EE03, binimetinib, The metabolism of Binimetinib can be decreased when combined with Thiothixene.]
[C07AB08, celiprolol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Celiprolol.]
[L01XX62, ivosidenib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ivosidenib.]
[N03AX17, stiripentol, The metabolism of Thiothixene can be decreased when combined with Stiripentol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Thiothixene.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Thiothixene is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Thiothixene.]
[R06AA06, chlorphenoxamine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[R03DA02, oxtriphylline, The metabolism of Thiothixene can be decreased when combined with Oxtriphylline.]
[N07XX15, inotersen, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Inotersen.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Thiothixene.]
[R03BB08, revefenacin, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Thiothixene can be increased when combined with Emapalumab.]
[L01AD01, carmustine, The metabolism of Thiothixene can be decreased when combined with Carmustine.]
[L01EX13, gilteritinib, The therapeutic efficacy of Thiothixene can be decreased when used in combination with Gilteritinib.]
[L01XJ03, glasdegib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Glasdegib.]
[N07XX05, amifampridine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Amifampridine.]
[C01BG07, cifenline, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Cibenzoline.]
[B01AC23, cilostazol, The risk or severity of QTc prolongation can be increased when Cilostazol is combined with Thiothixene.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Thiothixene is combined with Cinitapride.]
[P02BX04, triclabendazole, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Esketamine.]
[J01FA09, clarithromycin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Thiothixene.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Cloxazolam is combined with Thiothixene.]
[L04AB01, etanercept, The metabolism of Thiothixene can be increased when combined with Etanercept.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Cyamemazine.]
[C03BX03, cicletanine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Cicletanine.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Thiothixene.]
[L01EX14, entrectinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Entrectinib.]
[N07XX11, pitolisant, Thiothixene may increase the QTc-prolonging activities of Pitolisant.]
[J01XX12, lefamulin, Lefamulin may increase the QTc-prolonging activities of Thiothixene.]
[N04CX01, istradefylline, The therapeutic efficacy of Istradefylline can be decreased when used in combination with Thiothixene.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Yohimbine is combined with Thiothixene.]
[A10AE03, insulin, regular, pork, The metabolism of Thiothixene can be increased when combined with Insulin pork.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Thiothixene.]
[A16AX16, givosiran, The serum concentration of Thiothixene can be increased when it is combined with Givosiran.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Thiothixene.]
[R06AB02, dexchlorpheniramine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dexchlorpheniramine.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Dezocine is combined with Thiothixene.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Thiothixene is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Lumateperone is combined with Thiothixene.]
[M01AX21, diacetylrhein, The metabolism of Thiothixene can be decreased when combined with Diacerein.]
[S01AE06, gatifloxacin, The metabolism of Thiothixene can be decreased when combined with Gatifloxacin.]
[H02CA02, osilodrostat, The metabolism of Thiothixene can be decreased when combined with Osilodrostat.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Thiothixene.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Dichloralphenazone is combined with Thiothixene.]
[L01EE04, selumetinib, The metabolism of Selumetinib can be decreased when combined with Thiothixene.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Difenoxin is combined with Thiothixene.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Thiothixene.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Thiothixene.]
[M01AH02, rofecoxib, The metabolism of Thiothixene can be decreased when combined with Rofecoxib.]
[C01BD07, dronedarone, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Valpromide.]
[R06AE04, chlorcyclizine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Chlorcyclizine.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Thiothixene.]
[A03AA08, dihexyverine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[L01EX17, capmatinib, The metabolism of Thiothixene can be decreased when combined with Capmatinib.]
[N04BX04, opicapone, The therapeutic efficacy of Opicapone can be decreased when used in combination with Thiothixene.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Thiothixene.]
[G04BD09, trospium, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Thiothixene is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Chlormezanone is combined with Thiothixene.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Thiothixene.]
[R06AX22, ebastine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ebastine.]
[J05AX29, fostemsavir, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Fostemsavir.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Remimazolam.]
[N07XX04, sodium oxybate, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[L04AC19, satralizumab, The serum concentration of Thiothixene can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Thiothixene is combined with Oliceridine.]
[P01BA01, chloroquine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Chloroquine.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Chlorpheniramine is combined with Thiothixene.]
[N05AA01, chlorpromazine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.]
[N05AF03, chlorprothixene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Thiothixene.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Etifoxine.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Thiothixene.]
[B06AC06, berotralstat, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Berotralstat.]
[L02BX04, relugolix, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Relugolix.]
[L01FX21, naxitamab, Thiothixene may increase the neurotoxic activities of Naxitamab.]
[P03AX07, abametapir, The serum concentration of Thiothixene can be increased when it is combined with Abametapir.]
[V03AF12, trilaciclib, The metabolism of Thiothixene can be increased when combined with Trilaciclib.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Thiothixene is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Thiothixene.]
[N06BA10, fenethylline, The metabolism of Thiothixene can be decreased when combined with Fenethylline.]
[C01CA19, fenoldopam, The therapeutic efficacy of Fenoldopam can be decreased when used in combination with Thiothixene.]
[J01MB07, flumequine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Flumequine.]
[R03CC15, formoterol, The risk or severity of QTc prolongation can be increased when Formoterol is combined with Thiothixene.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Thiothixene.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The serum concentration of Thiothixene can be increased when it is combined with Peginterferon alfa-2b.]
[A02BA01, cimetidine, The metabolism of Thiothixene can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Thiothixene.]
[N07CA02, cinnarizine, The metabolism of Thiothixene can be decreased when combined with Cinnarizine.]
[J01MB06, cinoxacin, The metabolism of Thiothixene can be decreased when combined with Cinoxacin.]
[S03AA07, ciprofloxacin, The metabolism of Thiothixene can be decreased when combined with Ciprofloxacin.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Thiothixene is combined with Citalopram.]
[H01AC07, somapacitan, The metabolism of Thiothixene can be increased when combined with Somapacitan.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Thiothixene is combined with Fexinidazole.]
[H01AC09, lonapegsomatropin, The metabolism of Thiothixene can be increased when combined with Lonapegsomatropin.]
[L01EB10, mobocertinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Mobocertinib.]
[R06AA04, clemastine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Clemastine.]
[M01AG01, mefenamic acid, The metabolism of Thiothixene can be decreased when combined with Mefenamic acid.]
[J01FF01, clindamycin, Clindamycin may increase the neurotoxic activities of Thiothixene.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when St. John's Wort is combined with Thiothixene.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Thiothixene.]
[J04BA01, clofazimine, The risk or severity of QTc prolongation can be increased when Clofazimine is combined with Thiothixene.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Thiothixene.]
[L01EJ03, pacritinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of adverse effects can be increased when Clomipramine is combined with Thiothixene.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Clonazepam is combined with Thiothixene.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Thiothixene.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Clotiazepam is combined with Thiothixene.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Thiothixene.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Thiothixene.]
[N05AH02, clozapine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Clozapine.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Thiothixene.]
[H01AC08, somatrogon, The metabolism of Thiothixene can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Thiothixene may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Thiothixene can be increased when combined with Bimekizumab.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Thiothixene.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Thiothixene.]
[A03AB10, hexocyclium, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[L04AA13, leflunomide, The serum concentration of Thiothixene can be decreased when it is combined with Leflunomide.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Desflurane is combined with Thiothixene.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tropisetron.]
[C04AX28, ifenprodil, The therapeutic efficacy of Ifenprodil can be decreased when used in combination with Thiothixene.]
[J01FA15, telithromycin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Telithromycin.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Thiothixene.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Thiothixene.]
[J02AC02, itraconazole, The risk or severity of QTc prolongation can be increased when Itraconazole is combined with Thiothixene.]
[S01AD03, acyclovir, The metabolism of Thiothixene can be decreased when combined with Acyclovir.]
[S01GX06, emedastine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Emedastine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Ketazolam is combined with Thiothixene.]
[L01EA01, imatinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Imatinib.]
[J02AC04, posaconazole, The risk or severity of QTc prolongation can be increased when Posaconazole is combined with Thiothixene.]
[C08CA09, lacidipine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Lacidipine.]
[N03AX09, lamotrigine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[S01GX02, levocabastine, The risk or severity of QTc prolongation can be increased when Levocabastine is combined with Thiothixene.]
[N07BC04, lofexidine, The therapeutic efficacy of Thiothixene can be increased when used in combination with Lofexidine.]
[S01AE04, lomefloxacin, The metabolism of Thiothixene can be decreased when combined with Lomefloxacin.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Lormetazepam.]
[A03AA04, mebeverine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Medifoxamine.]
[R06AD07, mequitazine, Thiothixene may increase the arrhythmogenic activities of Mequitazine.]
[C01EB10, adenosine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Adenosine.]
[N04AA03, methixene, The therapeutic efficacy of Metixene can be decreased when used in combination with Thiothixene.]
[R03CB02, methoxyphenamine, Thiothixene may decrease the stimulatory activities of Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Cyclizine is combined with Thiothixene.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Thiothixene is combined with Cyclobarbital.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Thiothixene is combined with Melperone.]
[L01AA01, cyclophosphamide, Cyclophosphamide may increase the neurotoxic activities of Thiothixene.]
[N06AX07, minaprine, The risk or severity of adverse effects can be increased when Minaprine is combined with Thiothixene.]
[J04AB01, cycloserine, Cycloserine may increase the neurotoxic activities of Thiothixene.]
[S01XA18, cyclosporine, Cyclosporine may increase the neurotoxic activities of Thiothixene.]
[N06AG02, moclobemide, The risk or severity of adverse effects can be increased when Moclobemide is combined with Thiothixene.]
[N06BA07, modafinil, The metabolism of Thiothixene can be increased when combined with Armodafinil.]
[R06AX02, cyproheptadine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, The risk or severity of QTc prolongation can be increased when Moexipril is combined with Thiothixene.]
[J05AF10, entecavir, The metabolism of Thiothixene can be decreased when combined with Entecavir.]
[G04BE09, vardenafil, The risk or severity of QTc prolongation can be increased when Vardenafil is combined with Thiothixene.]
[M01AH05, etoricoxib, The metabolism of Etoricoxib can be decreased when combined with Thiothixene.]
[L01AX04, dacarbazine, The metabolism of Thiothixene can be decreased when combined with Dacarbazine.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Dantrolene is combined with Thiothixene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Deanol.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[M01AX01, nabumetone, The metabolism of Thiothixene can be decreased when combined with Nabumetone.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Nordazepam.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Niaprazine.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Thiothixene.]
[C01CA23, theodrenaline, The metabolism of Theodrenaline can be decreased when combined with Thiothixene.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Thiothixene.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Normethadone.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Thiothixene is combined with Escitalopram.]
[G04BD08, solifenacin, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[N06AA01, desipramine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Desipramine.]
[L01XA03, oxaliplatin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Oxaliplatin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Thiothixene.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Oxiracetam.]
[N04AA08, dexetimide, The therapeutic efficacy of Dexetimide can be decreased when used in combination with Thiothixene.]
[G04BD04, oxybutynin, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The metabolism of Thiothixene can be decreased when combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Thiothixene can be increased when combined with Adalimumab.]
[N06BA02, dextroamphetamine, Thiothixene may decrease the stimulatory activities of Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Thiothixene.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Thiothixene.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Dextromoramide is combined with Thiothixene.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Paroxetine.]
[B01AC04, clopidogrel, The metabolism of Thiothixene can be decreased when combined with Clopidogrel.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Diamorphine is combined with Thiothixene.]
[C04AD01, pentifylline, The metabolism of Pentifylline can be decreased when combined with Thiothixene.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Thiothixene.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Phenacemide is combined with Thiothixene.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Thiothixene.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Thiothixene is combined with Dibenzepin.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Thiothixene.]
[S01BC03, diclofenac, The metabolism of Thiothixene can be decreased when combined with Diclofenac.]
[J05AD01, foscarnet, The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Thiothixene.]
[A03AA07, dicyclomine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may increase the neurotoxic activities of Thiothixene.]
[A03AX04, pinaverium, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Pipamperone.]
[A03AB14, pipenzolate, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Erlotinib.]
[A08AA03, diethylpropion, Thiothixene may decrease the stimulatory activities of Diethylpropion.]
[C08CA03, isradipine, The risk or severity of QTc prolongation can be increased when Isradipine is combined with Thiothixene.]
[A03AB11, poldine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[C01AA04, digitoxin, The risk or severity of QTc prolongation can be increased when Digitoxin is combined with Thiothixene.]
[C01AA05, digoxin, The risk or severity of QTc prolongation can be increased when Digoxin is combined with Thiothixene.]
[C02DB01, dihydralazine, The metabolism of Thiothixene can be decreased when combined with Dihydralazine.]
[N02CA01, dihydroergotamine, The risk or severity of adverse effects can be increased when Dihydroergotamine is combined with Thiothixene.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Thiothixene.]
[J05AE08, atazanavir, The risk or severity of QTc prolongation can be increased when Atazanavir is combined with Thiothixene.]
[B01AC21, treprostinil, The risk or severity of QTc prolongation can be increased when Treprostinil is combined with Thiothixene.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Thiothixene.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Pridinol.]
[R06AB03, dimethindene, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[N03AG05, progabide, The therapeutic efficacy of Progabide can be decreased when used in combination with Thiothixene.]
[N06BC02, propentofylline, The metabolism of Propentofylline can be decreased when combined with Thiothixene.]
[R03DA03, proxyphylline, The metabolism of Proxyphylline can be decreased when combined with Thiothixene.]
[R06AA02, diphenhydramine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Thiothixene.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Quazepam is combined with Thiothixene.]
[N06BA11, dexmethylphenidate, The risk or severity of adverse effects can be increased when Thiothixene is combined with Dexmethylphenidate.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Quinupramine.]
[A03FA02, cisapride, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Cisapride.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Thiothixene.]
[C01BA03, disopyramide, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[P03AA04, disulfiram, The risk or severity of QTc prolongation can be increased when Disulfiram is combined with Thiothixene.]
[S02AA12, rifamycin SV, The metabolism of Thiothixene can be decreased when combined with Rifamycin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Thiothixene.]
[N05AX08, risperidone, The risk or severity of adverse effects can be increased when Risperidone is combined with Thiothixene.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Thiothixene.]
[J01MB01, rosoxacin, The risk or severity of QTc prolongation can be increased when Rosoxacin is combined with Thiothixene.]
[L01EX01, sunitinib, The risk or severity of QTc prolongation can be increased when Sunitinib is combined with Thiothixene.]
[L01XG01, bortezomib, The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Thiothixene.]
[C01EB18, ranolazine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ranolazine.]
[R03AC12, salmeterol, The risk or severity of QTc prolongation can be increased when Salmeterol is combined with Thiothixene.]
[A03FA03, domperidone, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Domperidone.]
[N06AA16, dothiepin, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Dosulepin.]
[N06AA12, doxepin, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Doxepin.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Thiothixene is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Sevoflurane is combined with Thiothixene.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Sibutramine.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Thiothixene is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Thiothixene.]
[C07AB13, talinolol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Talinolol.]
[J01MA05, temafloxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Temafloxacin.]
[D01BA02, terbinafine, The metabolism of Thiothixene can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Terodiline.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Thiothixene is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Thiothixene is combined with Thiopropazate.]
[G04BD01, emepronium, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Tianeptine is combined with Thiothixene.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Tofisopam.]
[N06AG03, toloxatone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Toloxatone.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Thiothixene.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Thiothixene.]
[L02BA02, toremifene, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Toremifene.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Thiothixene.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Thiothixene is combined with Triclofos.]
[A03AB08, tridihexethyl, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Thiothixene.]
[L02AE04, triptorelin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Triptorelin.]
[N04AA12, tropatepine, The therapeutic efficacy of Tropatepine can be decreased when used in combination with Thiothixene.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Thiothixene.]
[C02CA06, urapidil, The risk or severity of adverse effects can be increased when Thiothixene is combined with Urapidil.]
[J01MA04, enoxacin, The metabolism of Thiothixene can be decreased when combined with Enoxacin.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Thiothixene is combined with Veralipride.]
[L01CA04, vinorelbine, Vinorelbine may increase the neurotoxic activities of Thiothixene.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Thiothixene.]
[N06AX16, venlafaxine, The risk or severity of adverse effects can be increased when Venlafaxine is combined with Thiothixene.]
[N05CF02, zolpidem, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Thiothixene.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Zotepine.]
[C02AC02, guanfacine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Thiothixene.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Thiothixene.]
[G02AB03, ergonovine, The risk or severity of adverse effects can be increased when Ergometrine is combined with Thiothixene.]
[C04AE01, ergoloid mesylates, USP, The risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Thiothixene.]
[N02CA02, ergotamine, The risk or severity of adverse effects can be increased when Ergotamine is combined with Thiothixene.]
[N03AG01, valproic acid, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Valproic acid.]
[S01AA17, erythromycin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Estazolam is combined with Thiothixene.]
[H05BX01, cinacalcet, The metabolism of Thiothixene can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, The metabolism of Thiothixene can be decreased when combined with Estradiol.]
[G03CA57, estrogens, conjugated (USP), The metabolism of Thiothixene can be decreased when combined with Conjugated estrogens.]
[J04AK02, ethambutol, The metabolism of Thiothixene can be decreased when combined with Ethambutol.]
[C01CA15, gepefrine, Thiothixene may decrease the stimulatory activities of Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Thiothixene.]
[L02AA03, ethinyl estradiol, The metabolism of Thiothixene can be decreased when combined with Ethinylestradiol.]
[C01BD05, ibutilide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ibutilide.]
[N04AA05, profenamine, The therapeutic efficacy of Profenamine can be decreased when used in combination with Thiothixene.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Thiothixene.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Thiothixene.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Thiothixene.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Thiothixene.]
[L01CB01, etoposide, The metabolism of Thiothixene can be decreased when combined with Etoposide.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Thiothixene is combined with Sertindole.]
[C01BA05, ajmaline, The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Thiothixene.]
[L04AD02, tacrolimus, The risk or severity of QTc prolongation can be increased when Tacrolimus is combined with Thiothixene.]
[J01MA08, fleroxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Fleroxacin.]
[R06AX11, astemizole, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Astemizole.]
[R06AX12, terfenadine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Terfenadine.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Bupropion is combined with Thiothixene.]
[N06AB08, fluvoxamine, The metabolism of Thiothixene can be decreased when combined with Fluvoxamine.]
[C01BB03, tocainide, The metabolism of Thiothixene can be decreased when combined with Tocainide.]
[C01BC08, encainide, The risk or severity of QTc prolongation can be increased when Encainide is combined with Thiothixene.]
[L02AE02, leuprolide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Leuprolide.]
[A02BA03, famotidine, The risk or severity of QTc prolongation can be increased when Famotidine is combined with Thiothixene.]
[P02CA03, albendazole, The metabolism of Thiothixene can be increased when combined with Albendazole.]
[C08CA02, felodipine, The risk or severity of QTc prolongation can be increased when Felodipine is combined with Thiothixene.]
[C08EA01, fendiline, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Thiothixene.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Thiothixene.]
[R03CC02, albuterol, The risk or severity of QTc prolongation can be increased when Salbutamol is combined with Thiothixene.]
[G04BD02, flavoxate, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Thiothixene can be decreased when combined with Flecainide.]
[J02AC01, fluconazole, The risk or severity of QTc prolongation can be increased when Fluconazole is combined with Thiothixene.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Thiothixene.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Thiothixene is combined with Melitracen.]
[V03AZ01, ethanol, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC02, fluorouracil, The metabolism of Thiothixene can be decreased when combined with Fluorouracil.]
[N06AB03, fluoxetine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Thiothixene.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Thiothixene.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluspirilene.]
[L02BB01, flutamide, The metabolism of Thiothixene can be decreased when combined with Flutamide.]
[L01BC03, tegafur, The metabolism of Tegafur can be decreased when combined with Thiothixene.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Thiothixene is combined with Alcuronium.]
[G01AX06, furazolidone, The risk or severity of adverse effects can be increased when Furazolidone is combined with Thiothixene.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Thiothixene is combined with Eszopiclone.]
[N05AL05, amisulpride, Thiothixene may increase the antipsychotic activities of Amisulpride.]
[N06DA04, galantamine, The risk or severity of QTc prolongation can be increased when Galantamine is combined with Thiothixene.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Gallopamil.]
[N03AA04, barbexaclone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Barbexaclone.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Thiothixene is combined with Bifemelane.]
[C10AB04, gemfibrozil, The metabolism of Thiothixene can be decreased when combined with Gemfibrozil.]
[J01XA03, telavancin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Telavancin.]
[L02BX02, degarelix, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Degarelix.]
[L01EA02, dasatinib, The risk or severity of QTc prolongation can be increased when Dasatinib is combined with Thiothixene.]
[N04BC06, cabergoline, The therapeutic efficacy of Cabergoline can be decreased when used in combination with Thiothixene.]
[C01CA21, cafedrine, The metabolism of Cafedrine can be decreased when combined with Thiothixene.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Thiothixene.]
[L01EH01, lapatinib, The risk or severity of QTc prolongation can be increased when Lapatinib is combined with Thiothixene.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Thiothixene.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Glutethimide is combined with Thiothixene.]
[C01BD04, dofetilide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Dofetilide.]
[L01EX02, sorafenib, The risk or severity of QTc prolongation can be increased when Sorafenib is combined with Thiothixene.]
[C07AB09, esmolol, The risk or severity of QTc prolongation can be increased when Esmolol is combined with Thiothixene.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Thiothixene is combined with Fluindione.]
[L02AE03, goserelin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Goserelin.]
[P01BX01, halofantrine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Haloperidol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Halothane is combined with Thiothixene.]
[L02AE05, histrelin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Histrelin.]
[N05AH04, quetiapine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Thiothixene is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Thiothixene is combined with Allobarbital.]
[C09CA01, losartan, The risk or severity of QTc prolongation can be increased when Losartan is combined with Thiothixene.]
[N05CA16, hexobarbital, The risk or severity of adverse effects can be increased when Hexobarbital is combined with Thiothixene.]
[J05AG01, nevirapine, The metabolism of Thiothixene can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Nilvadipine.]
[R06AE06, oxatomide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Oxatomide.]
[C03AA03, hydrochlorothiazide, The risk or severity of QTc prolongation can be increased when Hydrochlorothiazide is combined with Thiothixene.]
[R05DA03, hydrocodone, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[G04BD06, propiverine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be increased when Hydroxychloroquine is combined with Thiothixene.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Thiothixene is combined with Prothipendyl.]
[N05BB01, hydroxyzine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Hydroxyzine.]
[B05CB02, sodium citrate, Thiothixene may increase the neurotoxic activities of Sodium citrate.]
[H01AC02, somatrem, The metabolism of Thiothixene can be increased when combined with Somatrem.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.]
[N06AA02, imipramine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Imipramine.]
[L01CD01, paclitaxel, Paclitaxel may increase the neurotoxic activities of Thiothixene.]
[H01BA04, terlipressin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Terlipressin.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Thiothixene.]
[C03BA11, indapamide, The risk or severity of QTc prolongation can be increased when Indapamide is combined with Thiothixene.]
[L03AB04, interferon alfa-2a, The metabolism of Thiothixene can be decreased when combined with Interferon alfa-2a.]
[L03AB05, interferon alfa-2b, The metabolism of Thiothixene can be decreased when combined with Interferon alfa-2b.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Thiothixene is combined with Milnacipran.]
[A03AA30, piperidolate, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Articaine.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Thiothixene.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Thiothixene.]
[R06AE01, buclizine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Anagrelide.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Thiothixene.]
[L03AB09, interferon alfacon-1, The metabolism of Thiothixene can be decreased when combined with Interferon alfacon-1.]
[J05AF04, stavudine, Stavudine may increase the neurotoxic activities of Thiothixene.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Thiothixene is combined with Iprindole.]
[N06AF05, iproniazid, The risk or severity of adverse effects can be increased when Thiothixene is combined with Iproniazid.]
[J05AB13, penciclovir, The metabolism of Thiothixene can be decreased when combined with Penciclovir.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, The risk or severity of adverse effects can be increased when Isocarboxazid is combined with Thiothixene.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Thiothixene.]
[N04BX02, entacapone, The therapeutic efficacy of Entacapone can be decreased when used in combination with Thiothixene.]
[J04AC01, isoniazid, The metabolism of Thiothixene can be decreased when combined with Isoniazid.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Thiothixene.]
[H01AC01, somatropin, The metabolism of Thiothixene can be increased when combined with Somatotropin.]
[L04AC07, tocilizumab, The metabolism of Thiothixene can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Ketamine is combined with Thiothixene.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Thiothixene is combined with Ketanserin.]
[J02AB02, ketoconazole, The metabolism of Thiothixene can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.]
[V03AC03, deferasirox, The serum concentration of Thiothixene can be increased when it is combined with Deferasirox.]
[L04AA24, abatacept, The metabolism of Thiothixene can be increased when combined with Abatacept.]
[R06AX25, mizolastine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Mizolastine.]
[N04BC09, rotigotine, Thiothixene may increase the sedative activities of Rotigotine.]
[J01MB02, nalidixic acid, The metabolism of Thiothixene can be decreased when combined with Nalidixic acid.]
[N04BB01, amantadine, The therapeutic efficacy of Amantadine can be decreased when used in combination with Thiothixene.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Lacosamide.]
[N04BA01, levodopa, The therapeutic efficacy of Levodopa can be decreased when used in combination with Thiothixene.]
[S02DA01, lidocaine, The metabolism of Thiothixene can be decreased when combined with Lidocaine.]
[C08EX01, lidoflazine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Lidoflazine.]
[J01FF02, lincomycin, Thiothixene may increase the neurotoxic activities of Lincomycin.]
[N06BA13, armodafinil, The metabolism of Thiothixene can be increased when combined with Armodafinil.]
[N02CA07, lisuride, The therapeutic efficacy of Lisuride can be decreased when used in combination with Thiothixene.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Loperamide.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Thiothixene.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Thiothixene.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Thiothixene can be increased when used in combination with Magnesium sulfate.]
[L01EA03, nilotinib, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Nilotinib.]
[N06AA21, maprotiline, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Thiothixene.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Thiothixene.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Thiothixene is combined with Medazepam.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be increased when Mefloquine is combined with Thiothixene.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Melatonin is combined with Thiothixene.]
[N06DX01, memantine, The therapeutic efficacy of Memantine can be decreased when used in combination with Thiothixene.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Thiothixene.]
[C01CA11, mephentermine, Thiothixene may decrease the stimulatory activities of Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Thiothixene.]
[N03AA01, mephobarbital, The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Thiothixene.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Thiothixene.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Thiothixene.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Meptazinol.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Thiothixene.]
[N05AX13, paliperidone, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Paliperidone.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Thiothixene.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Thiothixene.]
[N06BA03, methamphetamine, Thiothixene may decrease the stimulatory activities of Metamfetamine.]
[A03AB07, methantheline, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Thiothixene is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Thiothixene is combined with Methaqualone.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Thiothixene.]
[G02CB05, metergoline, The risk or severity of adverse effects can be increased when Thiothixene is combined with Metergoline.]
[H03BB02, methimazole, The metabolism of Thiothixene can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, The metabolism of Thiothixene can be decreased when combined with Pemetrexed.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Thiothixene.]
[N05CA15, methohexital, The risk or severity of adverse effects can be increased when Methohexital is combined with Thiothixene.]
[N02BG08, ziconotide, The risk or severity of CNS depression can be increased when Thiothixene is combined with Ziconotide.]
[N05AA02, methotrimeprazine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[D05BA02, methoxsalen, The metabolism of Thiothixene can be decreased when combined with Methoxsalen.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Thiothixene.]
[V04CG05, methylene blue, The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylene blue.]
[R03DA05, aminophylline, The metabolism of Thiothixene can be decreased when combined with Aminophylline.]
[N06BA04, methylphenidate, The risk or severity of adverse effects can be increased when Thiothixene is combined with Methylphenidate.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Thiothixene.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Methyprylon is combined with Thiothixene.]
[N02CA04, methysergide, The risk or severity of adverse effects can be increased when Methysergide is combined with Thiothixene.]
[A03FA01, metoclopramide, The risk or severity of adverse effects can be increased when Metoclopramide is combined with Thiothixene.]
[P01AB01, metronidazole, The risk or severity of QTc prolongation can be increased when Metronidazole is combined with Thiothixene.]
[C01BB02, mexiletine, The metabolism of Thiothixene can be decreased when combined with Mexiletine.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Mianserin is combined with Thiothixene.]
[N02BB03, aminopyrine, The metabolism of Thiothixene can be decreased when combined with Aminophenazone.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Thiothixene.]
[G03XB01, mifepristone, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Mifepristone.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[N06BA12, lisdexamfetamine, Thiothixene may decrease the stimulatory activities of Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Molindone is combined with Thiothixene.]
[C01BD01, amiodarone, The metabolism of Thiothixene can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Thiothixene.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Thiothixene.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Thiothixene.]
[L04AB05, certolizumab pegol, The metabolism of Thiothixene can be increased when combined with Certolizumab pegol.]
[B02BX05, eltrombopag, The metabolism of Eltrombopag can be decreased when combined with Thiothixene.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Thiothixene.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Vecuronium is combined with Thiothixene.]
[N05CA02, amobarbital, The risk or severity of adverse effects can be increased when Amobarbital is combined with Thiothixene.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Thiothixene.]
[R03BB01, ipratropium bromide, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Fosphenytoin is combined with Thiothixene.]
[L03AB08, interferon beta-1b, The metabolism of Thiothixene can be decreased when combined with Interferon beta-1b.]
[N04BC04, ropinirole, The therapeutic efficacy of Ropinirole can be decreased when used in combination with Thiothixene.]
[J01CF06, nafcillin, The metabolism of Thiothixene can be increased when combined with Nafcillin.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Thiothixene is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Thiothixene.]
[L04AC03, anakinra, The metabolism of Thiothixene can be increased when combined with Anakinra.]
[N06BA01, amphetamine, Thiothixene may decrease the stimulatory activities of Amphetamine.]
[M02AA12, naproxen, The metabolism of Thiothixene can be decreased when combined with Naproxen.]
[N06AX21, duloxetine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Duloxetine.]
[N04BX01, tolcapone, The therapeutic efficacy of Tolcapone can be decreased when used in combination with Thiothixene.]
[S03AA01, neomycin, Neomycin may increase the neurotoxic activities of Thiothixene.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Thiothixene.]
[C01CX08, levosimendan, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Levosimendan.]
[N05AX14, iloperidone, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Iloperidone.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Desvenlafaxine.]
[N06AF02, nialamide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Nialamide.]
[C08CA04, nicardipine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Nicardipine.]
[P02DA01, niclosamide, The metabolism of Thiothixene can be decreased when combined with Niclosamide.]
[C08CA05, nifedipine, The metabolism of Thiothixene can be decreased when combined with Nifedipine.]
[C08CA06, nimodipine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Nimodipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Nitrazepam is combined with Thiothixene.]
[C08CA08, nitrendipine, The risk or severity of QTc prolongation can be increased when Nitrendipine is combined with Thiothixene.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Thiothixene.]
[N04BC05, pramipexole, The therapeutic efficacy of Pramipexole can be decreased when used in combination with Thiothixene.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Nomifensine.]
[S01AE02, norfloxacin, The risk or severity of QTc prolongation can be increased when Norfloxacin is combined with Thiothixene.]
[N06AA10, nortriptyline, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.]
[L03AB07, interferon beta-1a, The metabolism of Thiothixene can be decreased when combined with Interferon beta-1a.]
[H01CB02, octreotide, The risk or severity of QTc prolongation can be increased when Octreotide is combined with Thiothixene.]
[S02AA16, ofloxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Ofloxacin.]
[L04AC04, rilonacept, The metabolism of Thiothixene can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Thiothixene can be increased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Thiothixene is combined with Opium.]
[G02CB04, quinagolide, The therapeutic efficacy of Quinagolide can be decreased when used in combination with Thiothixene.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Thiothixene.]
[J01MB05, oxolinic acid, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Oxolinic acid.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Oxprenolol is combined with Thiothixene.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Thiothixene.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Oxymorphone is combined with Thiothixene.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Oxypertine.]
[A03AB03, oxyphenonium, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[H01BB02, oxytocin, The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Thiothixene.]
[N05AH05, asenapine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.]
[M03AC01, pancuronium, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[G04BE02, papaverine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Papaverine.]
[N05CC05, paraldehyde, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, The risk or severity of adverse effects can be increased when Thiothixene is combined with Pargyline.]
[J01MA03, pefloxacin, The risk or severity of QTc prolongation can be increased when Pefloxacin is combined with Thiothixene.]
[G04BD11, fesoterodine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Penbutolol is combined with Thiothixene.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Thiothixene is combined with Penfluridol.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Thiothixene.]
[N05CA01, pentobarbital, The risk or severity of adverse effects can be increased when Pentobarbital is combined with Thiothixene.]
[C04AD03, pentoxifylline, The metabolism of Thiothixene can be decreased when combined with Pentoxifylline.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Thiothixene.]
[C08EX02, perhexiline, The risk or severity of QTc prolongation can be increased when Perhexiline is combined with Thiothixene.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Thiothixene.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Thiothixene.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Phenazocine.]
[N06AF03, phenelzine, The risk or severity of adverse effects can be increased when Phenelzine is combined with Thiothixene.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Thiothixene is combined with Phenindione.]
[R06AB05, pheniramine, The risk or severity of QTc prolongation can be increased when Pheniramine is combined with Thiothixene.]
[N03AA02, phenobarbital, The risk or severity of adverse effects can be increased when Phenobarbital is combined with Thiothixene.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Phenoperidine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Thiothixene is combined with Phenprocoumon.]
[A08AA01, phentermine, Thiothixene may decrease the stimulatory activities of Phentermine.]
[S01GA05, phenylephrine, The metabolism of Thiothixene can be increased when combined with Phenylephrine.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Thiothixene.]
[L04AB06, golimumab, The metabolism of Thiothixene can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Levofloxacin.]
[C08CX01, mibefradil, The metabolism of Thiothixene can be decreased when combined with Mibefradil.]
[N05AG02, pimozide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Pimozide.]
[C07AA03, pindolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Thiothixene.]
[J05AE01, saquinavir, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Pipotiazine is combined with Thiothixene.]
[A02BX03, pirenzepine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N04BC08, piribedil, The therapeutic efficacy of Piribedil can be decreased when used in combination with Thiothixene.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Thiothixene is combined with Piritramide.]
[J01MA11, grepafloxacin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Grepafloxacin.]
[N02CX01, pizotyline, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Thiothixene is combined with Proxibarbal.]
[A03AE01, alosetron, The metabolism of Thiothixene can be decreased when combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Thiothixene can be increased when combined with Canakinumab.]
[S03AA03, polymyxin B, Thiothixene may increase the neurotoxic activities of Polymyxin B.]
[J05AE03, ritonavir, The risk or severity of QTc prolongation can be increased when Ritonavir is combined with Thiothixene.]
[C01BA08, prajmaline, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Prajmaline.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Prazepam is combined with Thiothixene.]
[P02BA01, praziquantel, The metabolism of Thiothixene can be decreased when combined with Praziquantel.]
[R06AX05, antazoline, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Antazoline.]
[C01DX02, prenylamine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Thiothixene.]
[P01BA03, primaquine, The metabolism of Thiothixene can be increased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Thiothixene can be increased when combined with Primidone.]
[C10AX02, probucol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Probucol.]
[C01BA02, procainamide, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Procainamide.]
[S01HA05, procaine, The risk or severity of adverse effects can be increased when Procaine is combined with Thiothixene.]
[L01XB01, procarbazine, The risk or severity of adverse effects can be increased when Procarbazine is combined with Thiothixene.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Thiothixene.]
[N04AA04, procyclidine, The therapeutic efficacy of Procyclidine can be decreased when used in combination with Thiothixene.]
[N05AA03, promazine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Promazine.]
[R06AD02, promethazine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The metabolism of Thiothixene can be decreased when combined with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Thiothixene is combined with Propanidid.]
[A03AB05, propantheline, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The risk or severity of adverse effects can be increased when Periciazine is combined with Thiothixene.]
[N05CM06, propiomazine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Propiomazine.]
[L01XH02, romidepsin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Romidepsin.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Thiothixene.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Thiothixene.]
[C07AA05, propranolol, The metabolism of Thiothixene can be decreased when combined with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Thiothixene.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Thiothixene.]
[R01BA02, pseudoephedrine, Thiothixene may decrease the stimulatory activities of Pseudoephedrine.]
[N05AX12, aripiprazole, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.]
[A03AB15, diphemanil, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Thiothixene.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Thiothixene is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Thiothixene is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Thiothixene is combined with Pyrantel.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Thiothixene is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Thiothixene can be decreased when combined with Quinidine.]
[P01BC01, quinine, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Thiothixene can be decreased when combined with Ranitidine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Thiothixene.]
[J04AB02, rifampin, The metabolism of Thiothixene can be increased when combined with Rifampicin.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Thiothixene is combined with Oxitriptan.]
[J01FA06, roxithromycin, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Roxithromycin.]
[S01FA02, scopolamine, Thiothixene may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, The risk or severity of adverse effects can be increased when Secobarbital is combined with Thiothixene.]
[N04BD01, selegiline, The therapeutic efficacy of Selegiline can be decreased when used in combination with Thiothixene.]
[C07AA07, sotalol, The risk or severity of QTc prolongation can be increased when Thiothixene is combined with Sotalol.]
